Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiovascular (CV) Risk Clear all
Completed Phase 3 Interventional Results available

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT03415178
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY), Atorvastatin, Rosuvastatin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
13
States / cities
Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 31, 2026, 2:28 PM EDT
Recruiting Phase 2 Interventional

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

NCT07223385
View directory record Official record
Conditions
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
Interventions
Cardio-Oncology Referral, Notification to PCP/General Cardiologist
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Recruiting No phase listed Observational

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

NCT07284082
View directory record Official record
Conditions
HIV, Menopause, Cardiovascular (CV) Risk, Carotid Arteriosclerosis, Body Composition
Interventions
Whole body MRI
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

NCT02560805
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
Procedure · Behavioral · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Completed Phase 4 Interventional

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691
View directory record Official record
Conditions
Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
181
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated May 3, 2007 · Synced Oct 31, 2026, 2:28 PM EDT
Not yet recruiting Phase 3 Interventional

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

NCT07900633
View directory record Official record
Conditions
Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Apache Junction, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Not yet recruiting Not applicable Interventional

Evaluation of Community Health Worker Support to Help People With Serious Mental Illness to Quit Smoking

NCT07789132
View directory record Official record
Conditions
Nicotine Dependance, Serious Mental Illness, Smoking (Tobacco) Addiction, Tobacco Cessation, Community Health Workers, Cardiovascular (CV) Risk, Tobacco Use Disorder
Interventions
Integrated CHW Support intervention, Enhanced usual care (EUC)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 31, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

NCT07166822
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Exercise
Interventions
Experimental group using BumptUp mobile exercise app
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 31, 2026, 2:28 PM EDT
Completed No phase listed Observational

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

NCT00681759
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2008 · Synced Oct 31, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

NCT02104817
View directory record Official record
Conditions
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions
Epanova® (omega-3 carboxylic acids), corn oil control
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
13,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
229
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 31, 2026, 2:28 PM EDT
Completed Not applicable Interventional Results available

Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)

NCT04450914
View directory record Official record
Conditions
Cardiovascular Risk, Cardiovascular Prevention
Interventions
CV Prevention Choice Tool, Implementation Facilitation Strategies
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 75 Years
Enrollment
112,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Marietta, Georgia • Rochester, Minnesota • Grand Forks, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Ezetimibe, Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 31, 2026, 2:28 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Lions Hearts: A Community Approach to Multigenerational Cardiovascular Disease Risk

NCT07147387
View directory record Official record
Conditions
Cardiovascular (CV) Risk
Interventions
Lion Hearts Family-Based Physical Activity Program
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
10 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Better Adherence to Therapeutic Lifestyle Change Efforts Trial

NCT00458874
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
CIMT results
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 31, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pulses: Optimizing Pulse Consumption for Cardiometabolic Health

NCT06861153
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Healthy Eating Index, HbA1c, Lipid Profile, CRP
Interventions
Pulses 1.5 cups Group, Pulses 3 cups Group, My Plate Group (Control)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 31, 2026, 2:28 PM EDT
Completed No phase listed Observational

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

NCT07096063
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
887,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 31, 2026, 2:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Breast Artery Calcification (BAC) and Female Cardiovascular Disease

NCT07809932
View directory record Official record
Conditions
Cardiovascular Health Risk Communication, Cardiovascular (CV) Risk, Cardiovascular Disease Prevention
Interventions
Cardiac CT Scan, Bloodwork
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
55 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Suspended No phase listed Observational

Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors

NCT01740739
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Mission Viejo, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 31, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

Circadian Mechanisms, Glucose, and CV Risks in T1D

NCT06624046
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Sleep stability intervention
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 31, 2026, 2:28 PM EDT
Completed Not applicable Interventional Results available

Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness

NCT06025721
View directory record Official record
Conditions
Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension, Hyperlipidemias
Interventions
Cardiovascular Risk Homeless Support
Behavioral
Lead sponsor
Katherine Vickery
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 31, 2026, 2:28 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Neqpiaput Iinruugut (Our Food Is Medicine): A Tribally Driven Food Sovereignty Intervention to Reduce Heart Disease Risk in Alaska Native Adults

NCT07897838
View directory record Official record
Conditions
Cardiovascular (CV) Risk
Interventions
Neqpiaput linruugut (Our Food is Medicine)
Behavioral
Lead sponsor
University of Alaska Fairbanks
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fairbanks, Alaska
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 31, 2026, 2:28 PM EDT